J. Caers Archives - Page 4 of 4

P.14 Bendamustin shows distinct anti-tumoural responses in multiple myeloma patients that relapsed after prior bortezomib and lenalidomide treatment. A study on behalf of the MM BHS subcommittee

BJH - 2013, issue BHS Abstractbook, january 2013

J. Caers MD, PhD, M-C. Vekemans MD, I. Vande Broek MD, PhD, P.H. Mineur , K. Beel MD, PhD, V. Maertens MD, C. Schuermans MD, F. Leleu , G. Vanstraelen , H. Demuynck MD, W. Schroyens MD, PhD, E. Van den Neste MD, PhD, G. Bries MD, PhD, A. Van de Velde MD, M. Delforge MD, PhD, C. Doyen MD, PhD

P.33 Hematological and molecular responses in a case of refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) treated by Lenalidomide

BJH - 2013, issue BHS Abstractbook, january 2013

K. Hafraoui , J. Caers MD, PhD, F. Tassin , Y. Beguin MD, PhD

P.39 Simultaneous diagnosis of CLL and CML in a single patient with evidence for two different cell clones

BJH - 2013, issue BHS Abstractbook, january 2013

C. Bonnet MD, PhD, C. Menten , F. Lambert MD, A. Gothot MD, PhD, F. Baron MD, PhD, J. Caers MD, PhD, C. Herens , Y. Beguin MD, PhD

P.73 The immunomodulating peptide thymosin alpha 1 has no effects on multiple myeloma evolution and on immune reconstitution

BJH - 2013, issue BHS Abstractbook, january 2013

M. Binsfeld , E. Otjacques , M. Hannon , S. Dubois , Y. Beguin MD, PhD, F. Baron MD, PhD, J. Caers MD, PhD

J. Caers MD, PhD

Articles

P.14 Bendamustin shows distinct anti-tumoural responses in multiple myeloma patients that relapsed after prior bortezomib and lenalidomide treatment. A study on behalf of the MM BHS subcommittee

P.33 Hematological and molecular responses in a case of refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) treated by Lenalidomide

P.39 Simultaneous diagnosis of CLL and CML in a single patient with evidence for two different cell clones

P.73 The immunomodulating peptide thymosin alpha 1 has no effects on multiple myeloma evolution and on immune reconstitution